Exicure Inc

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors.

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports second quarter 2023 financial results and provides corporate update.

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports first quarter 2023 financial results and provides corporate update.

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim as Chief Executive Officer and Chief Financial Officer of t.

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on May 17, 2023 notifying the Company that, as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”).

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CHICAGO--(BUSINESS WIRE)--Exicure has invested in Cyworld Z Co. Ltd. through the purchase of $1 million aggregate principal amount of convertible bonds issued by Cyworld Z.

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Parts Id Inc

Wunong Net Technology Co Ltd

Nano-cap penny stocks are arguably the most volatile and speculative investments you can make other than nano-cap cryptos. Shares of these small businesses generally have a market capitalization lower than $50 million.

3 Nano-Cap Penny Stocks to Buy for Explosive Gains in 2023

CHICAGO--(BUSINESS WIRE)--Exicure, Inc., reported financial results for the year ended December 31, 2022 and provided an update on its business strategy and corporate progress.

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Exicure today announced the closing of the previously-announced private placement transaction with CBI USA, Inc. effective February 24, 2023.

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Akebia Therapeutics

Astra Space

SoFi Technologies

Volitionrx Limited

X4 Pharmaceuticals Inc

Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 6 Insider Picks Before 2023

Insiders are buying these penny stocks but are they worth the risk? The post 3 Top Penny Stocks To Buy According To Insiders Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks To Buy According To Insiders Before 2023

CHICAGO--( BUSINESS WIRE )--Exicure, Inc. (NASDAQ: XCUR) an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced the termination of its collaboration agreements with AbbVie, Inc. (AbbVie) and Ipsen BioPharm Limited (Ipsen).

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

CHICAGO--( BUSINESS WIRE )--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the quarter ended September 30, 2022 and provided an update on its business strategy and corporate progress.

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Exicure announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value.

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

CHICAGO--(BUSINESS WIRE)--Exicure CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference.

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

CHICAGO--(BUSINESS WIRE)--Exicure today reported financial results for the quarter ended June 30, 2022 and provided an update on its business strategy and corporate progress.

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC informing it that Nasdaq has confirmed that the Company has regained compliance with the $1.00 per share mini

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

A reverse stock split of Exicure, Inc. (NASDAQ: XCUR) of 1-for-30 has gone into effect. These are the details.

Exicure (XCUR) Stock: 1-For-30 Reverse Split Goes Into Effect

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that, following the implementation of a one-for-thirty reverse stock split at 5:00 p.m. EDT today, the Company's common stock will begin trading on a split-adjusted basis on Nasdaq effective with the open of business to

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that the Company's Annual Meeting of Stockholders (the “Annual Meeting”) held in virtual format on Friday, May 27, 2022 at 1:00 p.m. Central Time, was convened and adjourned until June 10, 2022 at 1:00 p.m. Central Time

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

BitNile Holdings

Waitr Holdings Inc

Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 20th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on May 20th

CHICAGO--(BUSINESS WIRE)--Exicure today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference.

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

CHICAGO--(BUSINESS WIRE)--Exicure today reported financial results for the quarter ended March 31, 2022 and provided an update on its business strategy and corporate progress.

Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress

CHICAGO--(BUSINESS WIRE)--Exicure, Inc.® (NASDAQ:XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that it has agreed to sell an aggregate of 26,021,111 shares of its common stock at a purchase price of $0.1937 per share to certain accredited investors in a private placement in public equity (“PIPE”) financing. The p

Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.

News for Exicure Inc Stock (XCUR)